logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

December 2017

ALXN 1210 for Paroxysmal Nocturnal Haemoglobinuria – First Line

ALXN1210 is an antibody under development that prevents the destruction of red blood cells (RBCs). The drug is administered by intravenous injection that requires fewer dosing regimen compared to current treatment option. If ALXN1210 is licensed for use in the UK, it could represent an additional treatment option for patients with paroxysmal nocturnal haemoglobinuria.  

Drugs

December 2017

Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

Lenalidomide in combination with bortezomib and dexamethasone is being developed for the treatment of adult patients with MM. While each of these drugs are already approved for treating a range of malignant blood diseases, the combination of the three drugs has shown significant potential particularly for the treatment of newly diagnosed MM. If approved, it …

Drugs

December 2017

IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma

There are currently few effective treatments available for advanced or metastatic uveal melanoma, including surgery to remove the cancer, radiotherapy or chemotherapy. IMCgp100 is a drug under development that would enable the body’s own immune system to recognise and specifically target and kill cancer cells.

Drugs

December 2017

Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line

The combination of ribociclib, fulvestrant, and buparlisib or alpelisib is being developed for the treatment of HR+ and HER2- locally recurrent or advanced metastatic breast cancer. Ribociclib is given by mouth (capsules). It acts by helping to slow the progression of cancer by inhibiting two certain types of proteins that play a role in ensuring …

Drugs

December 2017

Venetoclax in Combination with Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukaemia – First Line

Venetoclax is a drug that attaches to a protein in the body called Bcl-2. This protein presents in high amounts in CLL cancer cells, where it helps the cancer cells survive for longer in the body and makes them resistant to cancer medicines. Venetoclax causes the death of cancer cells and thereby slows the progression …

Drugs

December 2017

Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line

Veliparib is a new oral drug that is being developed for patients with HER2- breast cancer that is advanced and cannot be removed completely through surgery. The drug acts by targeting specific enzymes involved in the repair of damaged DNA that helps the body to kill cancer cells while allowing ordinary cells to survive.

Drugs

December 2017

Taselisib in Combination with Fulvestrant for Advanced ER Positive, HER2-negative Breast Cancer – Second Line After Aromatase Inhibitor Therapy

Taselisib is investigated as a new oral treatment for ER+, HER2- type of breast cancer. It is being investigated as a medicine to work on a pathway regulating cell growth and cell survival. If taken in combination with an intramuscular injection of fulvestrant, which stops the effect of hormones altering the breast cells, taselisib has the potential to prolong survival.

Drugs

December 2017

Alpelisib in Combination with Fulvestrant for Advanced HR Positive, HER2-negative Breast Cancer in Men and Postmenopausal Women

Alpelisib is a new drug that is being developed for patients with the HR+/HER2- type of advanced breast cancer. Alpelisib targets a very specific enzyme that transmits signals to cells, stopping the growth and survival of cancer cells.

Drugs

December 2017

Guadecitabine for Treatment of Naïve Acute Myeloid Leukaemia

Guadecitabine is a new treatment being developed for patients who have not received prior treatment (treatment naïve) and are ineligible to undergo intensive chemotherapy.

Drugs

October 2017

Nivolumab (Opdivo) in combination with platinum

Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer …

Get Alerts